(Carbidopa + levodopa) is a Small Molecule owned by Amneal Pharmaceuticals, and is involved in 5 clinical trials, which were completed.

Carbidopa acts by inhibiting the activity of dopa decarboxylase and levodopa acts by enhancing the activity of dopaminergic receptors (D1A, D1B, D2, D3, D4 and D5). DOPA decarboxylase is the enzyme which converts levodopa into dopamine to stimulate the dopaminergic receptors in the brain. Carbidopa acts by inhibiting the activity of DOPA decarboxylase. This decreases the conversion of levodopa into dopamine in peripheral tissues and compensate for the depleted supply in CNS. Carbidopa also prevents the metabolism of levodopa thereby increases its bio-availability.

The revenue for (Carbidopa + levodopa) is expected to reach a total of $1.4bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the (Carbidopa + levodopa) NPV Report.

(Carbidopa + levodopa) is currently owned by Amneal Pharmaceuticals.

(Carbidopa + levodopa) Overview

IPX-203 is an extended-release formulation of carbidopa in combination with levodopa is under development for the treatment of Parkinson’s disease. The drug candidate is a small molecule. It is administered through oral route. IPX203 contains two different drugs called levodopa and carbidopa in one capsule.Levodopa acts by targeting dopaminergic receptors and carbidopa acts by targeting DOPA decarboxylase. It is developed based on controlled-release delivery technology. 

Amneal Pharmaceuticals Overview

Amneal Pharmaceuticals (Amneal), formerly Amneal Pharmaceuticals, is a pharmaceutical company that develops, manufactures, markets and distribute pharmaceutical drug. It offering products includes generic and specialty pharmaceutical products. The company also offers product such as Activella, Albenza, Dexedrine, Nizatidine Oral Solution and Pyridiu in the area of oncology, inflammation and pain, central nervous system disorders, endocrinology and parasitic infections. Amneal offers products in various dosage forms such as oral solids and liquids, injectables, topicals, creams and ointments, transdermals, inhalation, ophthalmic and otic liquids and other device driven products. The company has operational presence in India, Switzerland, Ireland and the U.K. Amneal is headquartered in Bridgewater, New Jersey, the US.

The company reported revenues of (US Dollars) US$2,093.7 million for the fiscal year ended December 2021 (FY2021), an increase of 5.1% over FY2020. In FY2021, the company’s operating margin was 7.3%, compared to an operating margin of 4.6% in FY2020. In FY2021, the company recorded a net margin of 0.5%, compared to a net margin of 4.6% in FY2020. The company reported revenues of US$545.6 million for the third quarter ended September 2022, a decrease of 2.5% over the previous quarter.

Quick View – (Carbidopa + levodopa)

Report Segments
  • Innovator
Drug Name
  • (Carbidopa + levodopa)
Administration Pathway
  • Oral
Therapeutic Areas
  • Central Nervous System
Key Companies
Highest Development Stage
  • Pre-Registration

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.